ReviewJournal of translational medicine2026
Dysregulation of post-translational modifications in glioma: advances in pathological mechanisms and clinical targeting strategies.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-translational modifications (PTMs) are key epigenetic regulators modulating glioma initiation, progression, and therapeutic response by regulating target proteins’ properties. Major PTM subtypes (phosphorylation, ubiquitination, SUMOylation, acetylation, succinylation, lactylation, glycosylation, and methylation) have context-dependent roles; their dysregulation disrupts homeostasis, promoting oncogene activation, stemness, and TMZ resistance. However, PTM cross-regulation, redundancy, and clinical translation remain unclear.
methodsThis review adopts a comprehensive perspective to summarize advances on PTM dysregulations in gliomas. It synthesizes findings on the regulatory roles of each major PTM subtype in glioma pathophysiology, their functional impacts on glioma biological processes, and the implications of PTM dysregulation in therapeutic resistance.
resultsPhosphorylation drives critical cell signaling transduction, like mTOR and EGFR signaling cascades. Ubiquitination regulates the stability of key oncoproteins, and SUMOylation regulates nuclear processes and protein localization. Acetylation, succinylation, and lactylation are metabolite-dependent PTMs, which are closely coupled to glioma metabolic reprogramming. Histone methylation dynamically remodels chromatin accessibility to regulate gene transcription, while non-histone methylation bridges cellular signaling with epigenetic regulation. Glycosylation enhances tumor cell adhesion and invasiveness. Notably, dysregulation of these PTMs is consistently associated with glioma progression and TMZ resistance, yet the cross-regulatory networks and functional redundancy among these PTMs remain understudied.
conclusionsThis review systematically integrates current understanding of PTM dysregulation in gliomas and highlights their coordinated regulatory roles. Also, we identify unresolved gaps in PTM crosstalk and clinical translation and provide a foundation for developing PTM-targeted precision therapies. CLINICAL TRAIT NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.